A genome-wide association study of antidepressant-induced mania
- PMID: 37236419
- DOI: 10.1016/j.pnpbp.2023.110800
A genome-wide association study of antidepressant-induced mania
Abstract
Antidepressant-induced mania (AIM) is a side effect of antidepressant treatment that is characterized by mania or hypomania after the start of medication. It is likely polygenic, but its genetic component remains largely unexplored. We aim to conduct the first genome-wide association study of AIM in 814 bipolar disorder patients of European ancestry. We report no significant findings from our single-marker or gene-based analyses. Our polygenic risk score analyses also did not yield significant results with bipolar disorder, antidepressant response, or lithium response. Our suggestive findings on the hypothalamic-pituitary-adrenal axis and the opioid system in AIM require independent replications.
Keywords: Antidepressant-induced mania; Bipolar disorder; Depression; Genome-wide association study; Pharmacogenetics.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of Competing Interest CCZ, AKT, and JLK hold patents for genetic markers related to psychotropic medication outcomes. JLK is a member of the Scientific Advisory Board of Myriad Neuroscience. The other authors reported no conflicts of interest related to this study.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources